Media headlines about Juniper Pharmaceuticals (NASDAQ:JNP) have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Juniper Pharmaceuticals earned a news impact score of 0.18 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 44.1564691835831 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

A number of equities research analysts have recently issued reports on JNP shares. ValuEngine upgraded Juniper Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. HC Wainwright restated a “neutral” rating on shares of Juniper Pharmaceuticals in a research report on Monday, November 6th. Finally, Roth Capital started coverage on Juniper Pharmaceuticals in a research report on Tuesday, January 2nd. They issued a “buy” rating and a $12.00 price target for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $23.00.

Juniper Pharmaceuticals (JNP) traded down $0.30 during mid-day trading on Friday, hitting $6.00. The stock had a trading volume of 40,200 shares, compared to its average volume of 61,583. The company has a quick ratio of 1.68, a current ratio of 2.00 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $68.32, a price-to-earnings ratio of 10.17 and a beta of 0.04. Juniper Pharmaceuticals has a 1-year low of $3.65 and a 1-year high of $6.40.

Juniper Pharmaceuticals (NASDAQ:JNP) last posted its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.09. Juniper Pharmaceuticals had a return on equity of 17.32% and a net margin of 10.80%. equities research analysts forecast that Juniper Pharmaceuticals will post -0.49 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Juniper Pharmaceuticals (JNP) Share Price” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-juniper-pharmaceuticals-jnp-share-price/1814022.html.

Juniper Pharmaceuticals Company Profile

Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.

Insider Buying and Selling by Quarter for Juniper Pharmaceuticals (NASDAQ:JNP)

Receive News & Ratings for Juniper Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.